Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230

Abstract

Background: Bullous pemphigoid (BP) is a prevalent autoimmune blistering disorder characterized by an immune response directed against the structural components of the dermal–epidermal junction, primarily BP180 and BP230. Literature Review: Further investigations by (Liu et al., 2017) emphasized the pathogenic role of IgG autoantibodies against BP180 in disease development, revealing that serum levels of these antibodies correlate with disease activity. This correlation suggests that these autoantibodies are not merely markers but may play a direct role in the pathophysiology of BP. The increasing morbidity associated with BP, especially in older populations, underscores the necessity for effective therapeutic interventions. (Didona & Di Zenzo, 2018) explored the concept of humoral epitope spreading, indicating that initial immune responses to BP180 could lead to reactivity against BP230, complicating the immune landscape of BP. This phenomenon is essential for understanding disease progression and its clinical implications. (Farnaghi et al., 2020) provided novel insights into the relationship between eosinophilia and BP severity, demonstrating that eosinophil levels correlate with autoantibody titers, suggesting eosinophilia may serve as a biomarker for disease activity. Conclusion: Collectively, these studies contribute to a comprehensive understanding of the interplay between autoantibody levels and clinical manifestations of BP. They emphasize the importance of serological assays in diagnosing and monitoring disease activity, showcasing the complexity of autoimmune responses and the need for ongoing research to refine therapeutic approaches.